Clarithromycin prophylaxis against Cryptosporidium enteritis in patients with AIDS

Area of Science:

• Infectious Diseases
• Immunology
• Gastroenterology

Background:

• Cryptosporidium enteritis (CE) is a severe opportunistic infection in patients with acquired immunodeficiency syndrome (AIDS).
• Low CD4 counts (<25/mm3) in AIDS patients correlate with a high risk and poor prognosis for CE.
• Prior to clarithromycin availability for Mycobacterium avium complex (MAC), CE posed a significant mortality risk.

Purpose of the Study:

• To evaluate the efficacy of clarithromycin as prophylaxis against Cryptosporidium enteritis (CE) in patients with acquired immunodeficiency syndrome (AIDS).
• To compare the incidence of CE in AIDS patients receiving clarithromycin for MAC prophylaxis versus those not receiving it.

Main Methods:

• Retrospective chart review of 471 AIDS patients.
• Comparative analysis of 136 AIDS patients (63 clarithromycin group, 73 control) with CD4 counts < 50/mm3.
• Prospective 2-year follow-up of 217 additional AIDS patients receiving clarithromycin prophylaxis.

Main Results:

• Seven AIDS patients with CD4 < 25/mm3 developed CE pre-clarithromycin, with a median survival of 10.6 days.
• No patients receiving clarithromycin prophylaxis developed CE, compared to four in the control group (all with CD4 < 25/mm3).
• All clarithromycin recipients remained stool-negative for Cryptosporidium; no CE cases observed in a subsequent 2-year follow-up.

Conclusions:

• Clarithromycin prophylaxis is highly effective in preventing Cryptosporidium enteritis in AIDS patients with low CD4 counts.
• These findings strongly support the use of clarithromycin for MAC prophylaxis to also prevent CE in this vulnerable population.
• Prophylactic clarithromycin significantly improves outcomes by preventing severe opportunistic infections like CE in AIDS patients.